These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 36529293)

  • 1. Beta-blockers in the era of precision medicine in patients with cirrhosis.
    Albillos A; Krag A
    J Hepatol; 2023 Apr; 78(4):866-872. PubMed ID: 36529293
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of non-selective beta blockers in cirrhosis: the evidence we need before closing (or not) the window.
    La Mura V; Tosetti G; Primignani M; Salerno F
    World J Gastroenterol; 2015 Feb; 21(8):2265-8. PubMed ID: 25741132
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Carvedilol versus traditional, non-selective beta-blockers for adults with cirrhosis and gastroesophageal varices.
    Zacharias AP; Jeyaraj R; Hobolth L; Bendtsen F; Gluud LL; Morgan MY
    Cochrane Database Syst Rev; 2018 Oct; 10(10):CD011510. PubMed ID: 30372514
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Beta-adrenergic blockade in cirrhosis - harmful or helpful?
    Møller S; Danielsen KV; Nabilou P; Kimer N; Bendtsen F
    Expert Rev Gastroenterol Hepatol; 2023; 17(6):519-529. PubMed ID: 37202907
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacologic prevention of variceal bleeding and rebleeding.
    Baiges A; Hernández-Gea V; Bosch J
    Hepatol Int; 2018 Feb; 12(Suppl 1):68-80. PubMed ID: 29210030
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Beta-blockers and cirrhosis: Striking the right balance.
    Cromer M; Wilcox CM; Shoreibah M
    Am J Med Sci; 2024 Apr; 367(4):228-234. PubMed ID: 38262558
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influence of further decompensation on survival across clinical stages of decompensated cirrhosis: The role of portal hypertension and HVPG changes.
    Garcia-Guix M; Ardevol A; Sapena V; Alvarado-Tápias E; Huertas A; Brujats A; Fajardo J; Cuyas B; Poca M; Guarner C; Torras X; Escorsell À; Villanueva C
    Liver Int; 2024 Aug; 44(8):1971-1989. PubMed ID: 38634685
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Beta adrenergic blockade and decompensated cirrhosis.
    Reiberger T; Mandorfer M
    J Hepatol; 2017 Apr; 66(4):849-859. PubMed ID: 27864004
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The portal hypertension syndrome: etiology, classification, relevance, and animal models.
    Bosch J; Iwakiri Y
    Hepatol Int; 2018 Feb; 12(Suppl 1):1-10. PubMed ID: 29064029
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Non-invasive response prediction in prophylactic carvedilol therapy for cirrhotic patients with esophageal varices.
    Kim HY; So YH; Kim W; Ahn DW; Jung YJ; Woo H; Kim D; Kim MY; Baik SK
    J Hepatol; 2019 Mar; 70(3):412-422. PubMed ID: 30389550
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Carvedilol as the new non-selective beta-blocker of choice in patients with cirrhosis and portal hypertension.
    Turco L; Reiberger T; Vitale G; La Mura V
    Liver Int; 2023 Jun; 43(6):1183-1194. PubMed ID: 36897563
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Non-selective beta-blockers in patients with ascites: The complex interplay among the liver, kidney and heart.
    Téllez L; Albillos A
    Liver Int; 2022 Apr; 42(4):749-761. PubMed ID: 35051310
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improving primary prophylaxis of variceal bleeding by adapting therapy to the clinical stage of cirrhosis. A competing-risk meta-analysis of individual participant data.
    Villanueva C; Sapena V; Lo GH; Seo YS; Shah HA; Singh V; Tripathi D; Schepke M; Gheorghe C; Bonilha DQ; Jutabha R; Wang HM; Rodrigues SG; Brujats A; Lee HA; Azam Z; Kumar P; Hayes PC; Sauerbruch T; Chen WC; Iacob S; Libera ED; Jensen DM; Alvarado E; Torres F; Bosch J;
    Aliment Pharmacol Ther; 2024 Feb; 59(3):306-321. PubMed ID: 38108646
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Review article: controversies surrounding the use of carvedilol and other beta blockers in the management of portal hypertension and cirrhosis.
    Gillespie SL; Hanrahan TP; Rockey DC; Majumdar A; Hayes PC
    Aliment Pharmacol Ther; 2023 Mar; 57(5):454-463. PubMed ID: 36691947
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of Nonselective β-Blockers in Patients With End-Stage Liver Disease and Select Complications.
    Bultas AC; Teshome B; Richter SK; Schafers S; Cooke E; Call WB
    Ann Pharmacother; 2020 Jun; 54(6):583-593. PubMed ID: 31810371
    [No Abstract]   [Full Text] [Related]  

  • 16. β-blockers in advanced cirrhosis: More friend than enemy.
    Yoon KT; Liu H; Lee SS
    Clin Mol Hepatol; 2021 Jul; 27(3):425-436. PubMed ID: 33317244
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Management of betablocked patients after sustained virological response in hepatitis C cirrhosis.
    Abadía M; Montes ML; Ponce D; Froilán C; Romero M; Poza J; Hernández T; Fernández-Martos R; Olveira A;
    World J Gastroenterol; 2019 Jun; 25(21):2665-2674. PubMed ID: 31210717
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular Profiling of Decompensated Cirrhosis by a Novel MicroRNA Signature.
    Garcia Garcia de Paredes A; Manicardi N; Tellez L; Ibañez L; Royo F; Bermejo J; Blanco C; Fondevila C; Fernandez Lanza V; Garcia-Bermejo L; Falcon-Perez JM; Bañares R; Gracia-Sancho J; Albillos A
    Hepatol Commun; 2021 Feb; 5(2):309-322. PubMed ID: 33553977
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Beta blockers and cirrhosis, 2016.
    Mandorfer M; Reiberger T
    Dig Liver Dis; 2017 Jan; 49(1):3-10. PubMed ID: 27717792
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Liver volume index predicts the risk of esophageal variceal hemorrhage in cirrhotic patients on propranolol prophylaxis.
    Kim BH; Chung JW; Lee CS; Jang ES; Jeong SH; Kim N; Kim JW
    Korean J Intern Med; 2019 Nov; 34(6):1233-1243. PubMed ID: 30759966
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.